Gene Therapy for Haemophilia A.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

January 31, 2029

Study Completion Date

December 31, 2029

Conditions
Hemophilia A
Interventions
BIOLOGICAL

AAV2/8-HLP-FVIII-V3

Infusion of AAV2/8-HLP-FVIII-V3

Trial Locations (4)

40506

University of Kentucky, Lexington

83712

St. Luke'S Regional Medical Center, Ltd, Boise

38105-3678

St Jude's Children's Research Hospital, Memphis

NW3 2QG

Royal Free Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

University College, London

OTHER